ArticleBacteriophage2011
Phage treatment of human infections.
Article in Bacteriophage, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 472 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
472 citing papers in PubMed, 2 syntheses or guidelines pooled it, 958 citations in OpenAlex.
- Evolutionary dynamics and research hotspots of phage applications againstFrontiers in microbiology · 2025Pooled it
- Reassessment of Historical Clinical Trials Supports the Effectiveness of Phage Therapy.Clinical microbiology reviews · 2022Pooled it
- Microbiota-constrained bacterial density limits phage infection in the gut and allows persistence of susceptible cells.iScience · 2026Article
- AApplied and environmental microbiology · 2026Article
- Polycationic Peptide Engineering of Phage Endolysins Expands Host Range and Enhances Antibacterial and Antibiofilm Activities Against Bacillus Species.Biotechnology and bioengineering · 2026Article
- Article
- Strain-level molecular and infection traits are associated with differences in phage efficacy against Pseudomonas aeruginosa.Scientific reports · 2026Article
- Therapeutic potential of a novel virulent bacteriophage XQ-1 against avian pathogenic Escherichia coli infection in broiler chickens.Poultry science · 2026Article
- Phage as a prospective arsenal against superbugs.Molecular biology reports · 2026Review
- Complementary Activities of Bacteriophages and Antimicrobial Peptide Dendrimers Against Prosthetic Joint Infection Pathogens.Bioengineering (Basel, Switzerland) · 2026Article
- Formulation-Level Tolerability of Repeated Drinking-Water Administration of a Commercial Multi-Component Bacteriophage Product in Ross 308 Broiler Chickens: A Pilot 27-Day Dose-Escalation Study.Veterinary sciences · 2026Article
- Characterization and therapeutic potential of two Kayvirus phages against methicillin-resistant S. aureus in a rat myositis model.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Mechanism ofMicroorganisms · 2026Article
- Biofilm-Binding Phages Enhance Biofilm Eradication by Synergistic Photothermal and Photodynamic Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Isolation, characterization, and proof of concept evaluation of serially adapted bacteriophages against multidrug-resistant Escherichia coli.Folia microbiologica · 2026Article
- Harnessing lytic phages for biofilm control in carbapenem-resistantMicrobiology spectrum · 2026Article
- Enamel Remineralizing Agents: State of the Art.Materials (Basel, Switzerland) · 2026Review
- Bacteriophage therapy for multidrug-resistant bacterial infections: recent advances, clinical evidence, and translational challenges.Archives of microbiology · 2026Review
- Comparative Study of Bacteriophage Pharmacokinetics by Different Enteral Administration Routes.Methods and protocols · 2026Article
- Single Treatment of Mature 3D Single-, Dual- and Poly-Species Biofilms Using a Combination Therapy of Phage or Phage-Hetero-Cocktails and Ciprofloxacin.Antibiotics (Basel, Switzerland) · 2026Article
412 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phages as bactericidal agents have been employed for 90 years as a means of treating bacterial infections in humans as well as other species, a process known as phage therapy. In this review we explore both the early historical and more modern use of phages to treat human infections. We discuss in particular the little-reviewed French early work, along with the Polish, US, Georgian and Russian historical experiences. We also cover other, more modern examples of phage therapy of humans as differentiated in terms of disease. In addition, we provide discussions of phage safety, other aspects of phage therapy pharmacology, and the idea of phage use as probiotics.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.